New York Post may be compensated and/or receive an affiliate commission if you click or buy through our links. Featured pricing is subject to change. Earlier this year, my wife and I welcomed our son ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: A U.S. flag stands next to the AstraZeneca logo during a signing event for documents related to a manufacturing site ...
(Reuters) -AstraZeneca has breached the UK pharmaceutical industry's code of practice, an industry self-regulatory body ruled on Friday, after incorrect claims related to the drugmaker's asthma ...
An initial dose of 0.3 mg intramuscular (IM) epinephrine was tied to a greater escalation of care than a dose of 0.5 mg in patients with anaphylaxis, a retrospective single-center study found. The ...
Oral semaglutide at a dose of 25 mg may provide an alternative treatment option to injectable semaglutide (2.4 mg) and higher-dose oral semaglutide (50 mg) for persons with overweight or obesity. In a ...
Chapped lips, peeling skin, nosebleeds — the drug treats acne, but its side effects can be miserable. Will a lower dose help? Credit...Eric Helgas for The New York Times Supported by By Erica Sweeney ...
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy Many drugs in development continue to follow the historical drug development ...
A more gradual titration significantly reduced the incidence of amyloid-related imaging abnormalities with edema/effusion. The Food and Drug Administration (FDA) has updated the labeling for Kisunla ™ ...
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) administered at off-label reduced dosing maintained weight-loss benefits, with patients retaining the effects even with 2-4 weeks between doses.
On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials ...
The MUSETTE trial found no additional benefit in higher doses of ocrelizumab for RMS compared to the standard 600 mg dose. The 600 mg dose of ocrelizumab remains optimal for slowing disability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results